Meprobamato [INN-Spanish]
Brand names,
Meprobamato [INN-Spanish]
Analogs
Meprobamato [INN-Spanish]
Brand Names Mixture
Meprobamato [INN-Spanish]
Chemical_Formula
C20H23NS
Meprobamato [INN-Spanish]
RX_link
No information avaliable
Meprobamato [INN-Spanish]
fda sheet
Meprobamato [INN-Spanish]
msds (material safety sheet)
Meprobamato [INN-Spanish]
Synthesis Reference
No information avaliable
Meprobamato [INN-Spanish]
Molecular Weight
309.469 g/mol
Meprobamato [INN-Spanish]
Melting Point
< 25 oC
Meprobamato [INN-Spanish]
H2O Solubility
Soluble as HCl salt
Meprobamato [INN-Spanish]
State
Liquid
Meprobamato [INN-Spanish]
LogP
5.7
Meprobamato [INN-Spanish]
Dosage Forms
Tablets (oral, 1 mg)
Meprobamato [INN-Spanish]
Indication
Used for the symptomatic treatment of parkinsonism.
Meprobamato [INN-Spanish]
Pharmacology
Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.
Meprobamato [INN-Spanish]
Absorption
Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.
Meprobamato [INN-Spanish]
side effects and Toxicity
Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
Meprobamato [INN-Spanish]
Patient Information
Meprobamato [INN-Spanish]
Organisms Affected
Humans and other mammals